| Market Cap | 78.95M | P/E | - | EPS this Y | 19.50% | Ern Qtrly Grth | - |
| Income | -47.57M | Forward P/E | -1.94 | EPS next Y | 36.60% | 50D Avg Chg | -2.00% |
| Sales | 10.16M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 7.00% |
| Dividend | N/A | Price/Book | 2.10 | EPS next 5Y | - | 52W High Chg | -55.00% |
| Recommedations | 2.20 | Quick Ratio | 1.60 | Shares Outstanding | 5.98M | 52W Low Chg | 69.00% |
| Insider Own | 0.18% | ROA | -45.97% | Shares Float | 4.96M | Beta | 3.32 |
| Inst Own | 38.87% | ROE | -372.68% | Shares Shorted/Prior | 143.37K/68.69K | Price | 0.79 |
| Gross Margin | -297.48% | Profit Margin | - | Avg. Volume | 287,417 | Target Price | 22.50 |
| Oper. Margin | -491.44% | Earnings Date | Oct 31 | Volume | 110,540 | Change | -2.61% |
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
| HC Wainwright & Co. | Buy | Aug 1, 24 |
| Truist Securities | Buy | May 15, 24 |
| HC Wainwright & Co. | Buy | May 15, 24 |
| Cantor Fitzgerald | Overweight | May 15, 24 |
| HC Wainwright & Co. | Buy | May 8, 24 |
| HC Wainwright & Co. | Buy | Feb 9, 24 |
| Truist Securities | Buy | Nov 17, 23 |